Butterfly Therapeutics

Butterfly Therapeutics was a French healthcare technology company focused on digital therapeutics for pain and anxiety management. Its main product, Bliss DTx, uses virtual reality augmented by sound and visual stimuli to manage procedural pain and anxiety. A clinical study showed that the device was clinically equivalent to standard protocols such as MEOPA or hypnotic/anxiolytic sedation during painful procedures like osteomedullary biopsy or port-a-cath insertion. The company targeted improved patient satisfaction and potential organizational/economic benefits through its technology. As of July 2023, the company filed for bankruptcy/liquidation. Butterfly Therapeutics operated out of Bègles near Bordeaux in France from at least 2017 until filing for bankruptcy/liquidation around July 2023 under the name Lucine—a closely related entity sharing address/investors/products/focus areas. Its core offering was Bliss DTx, a VR-based digital therapeutic targeting acute/procedural pain and anxiety via non-pharmacological means. At least one clinical trial was active as recently as mid–2024 assessing equivalence versus standard sedative protocols during invasive procedures like port-a-cath insertion. No evidence exists that it has been acquired or remains operational post-bankruptcy filing. No public trading symbol/exchange listing found. Key people not specified in available sources.